Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (NASDAQ:ACOG) reported Q1 2026 ZUNVEYL net product revenue of $3.5 million, up 40% sequentially, with cumulative launch revenue of $10.3 million. Bottles dispensed rose 23% to 6,054 and HCP writers increased 23% to 1,060.
Q1 operating expenses were $11.6 million, net loss was $6.5 million, and cash stood at $54.2 million. The company targets operating profitability in 2027, has Medicare Part D contracts covering about 45 million lives, and expects BEACON top-line data in early Q3 2026.
Alpha Cognition (Nasdaq: ACOG) will report Q1 2026 financial results and provide a business update on Thursday, May 14, 2026 at 4:30 p.m. ET after market close. A press release, materials, and a live webcast will be available on the company's investor news page. Management will host a conference call following the release.
Alpha Cognition (NASDAQ: ACOG) announced CEO Michael McFadden will participate in three investor conferences in May 2026: Market Movers Investor Summit (May 5), H.C. Wainwright BioConnect at Nasdaq (May 19), and Craig Hallum Institutional Investor Conference (May 28). Select presentations will be webcast and archived on the company investor relations website.
Alpha Cognition (Nasdaq: ACOG) appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of finance, strategy, and operations experience, including CFO roles at Radius Health and 9 Meters, and Biogen P&L responsibility for >$1 billion across 30 countries. The company said her expertise will support the commercial launch of ZUNVEYL and ongoing development of its sublingual program. Alpha Cognition also announced that founding director Len Mertz will not seek re-election after guiding the company to an FDA-approved product.
Alpha Cognition (NASDAQ: ACOG) announced inducement grants of nonstatutory stock options to a new non-executive employee under its 2026 Inducement Grant Plan dated April 14, 2026. The grant covers 20,000 options with an exercise price of $6.49 per share.
Options vest over three years: 25% at one year, then monthly over the next 24 months, and are subject to the plan and option agreement terms.
Alpha Cognition (NASDAQ: ACOG) announced the USPTO issued U.S. Patent No. 12,589,099 on March 31, 2026 for ALPHA-1062 to treat confirmed and suspected traumatic brain injury (TBI). The patent extends protection through 2045 and complements existing patents covering ALPHA-1062 and ZUNVEYL.
The company highlights a potential addressable market of $14 billion for TBI and positions the patent as strengthening long-term asset value and commercial opportunities for its pipeline.
Alpha Cognition (NASDAQ: ACOG) saw accelerating commercial traction for ZUNVEYL at the end of FY25. 4Q25 net product revenue reached $2.5M and FY25 revenue was $10.2M, including $6.8M from ZUNVEYL. Bottles dispensed rose 62% q/q to 4,941, with December at a record 1,859.
Adoption metrics show 729 ordering homes and 865 prescribers, with repeat orders at 82% and repeat writers at 69%. The company ended FY25 with $66.0M cash, which management says funds commercialization into 2027 and supports expected sequential sales growth in 2026.
Alpha Cognition (NASDAQ:ACOG) reported fiscal 2025 results and operational progress for ZUNVEYL on March 26, 2026. Q4 net product revenue was approximately $2.5M; full-year revenue was $10.2M, including $6.8M product and $3.4M licensing. Cash totaled $66.0M, supporting a ~two-year runway after a $40M October 2025 raise.
Commercial momentum: Q4 bottles dispensed 4,941 (+62% QoQ), December 1,859; Q4 prescribers +50% QoQ; two national PBM contracts in place. Ongoing and planned studies include BEACON, CONVERGE, and RESOLVE; additional patent issued and sublingual program advancing to clinic in 2026.
Alpha Cognition (Nasdaq: ACOG) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 at 4:30 p.m. ET, after market close.
Management will host a conference call and live webcast following the release; replay details and dial-in numbers will be available. Materials will be posted in the company's investor News section.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data on ZUNVEYL (benzgalantamine) at two upcoming conferences: the American Association of Geriatric Psychiatrists (April 16-20, 2026) and the Neuroscience Education Institute Spring Congress (May 1-3, 2026).
Multiple poster presentations will report on nicotinic receptor modulation, acetylcholinesterase inhibitor persistence, delayed nursing home placement, and psychotropic medication use in Alzheimer’s disease and related dementias.